FATE THERAPEUTICS INC (FATE)
US31189P1021 - Common Stock
Overall FATE gets a fundamental rating of 3 out of 10. We evaluated FATE against 565 industry peers in the Biotechnology industry. While FATE has a great health rating, there are worries on its profitability. FATE is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
FATE had negative earnings in the past year.
FATE had a negative operating cash flow in the past year.
FATE had negative earnings in each of the past 5 years.
In the past 5 years FATE always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of FATE (-33.23%) is better than 64.53% of its industry peers.
The Return On Equity of FATE (-44.26%) is better than 70.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.23% | ||
| ROE | -44.26% | ||
| ROIC | N/A |
ROA(3y)-31.58%
ROA(5y)-31.01%
ROE(3y)-44.38%
ROE(5y)-43.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for FATE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FATE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FATE has been increased compared to 1 year ago.
Compared to 5 years ago, FATE has more shares outstanding
FATE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
FATE has an Altman-Z score of -2.94. This is a bad value and indicates that FATE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of FATE (-2.94) is comparable to the rest of the industry.
FATE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.94 |
ROIC/WACCN/A
WACC10.41%
2.3 Liquidity
A Current Ratio of 9.18 indicates that FATE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.18, FATE is in the better half of the industry, outperforming 78.79% of the companies in the same industry.
A Quick Ratio of 9.18 indicates that FATE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.18, FATE is doing good in the industry, outperforming 78.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.18 | ||
| Quick Ratio | 9.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.20% over the past year.
The Revenue for FATE has decreased by -89.67% in the past year. This is quite bad
FATE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 68.05% yearly.
EPS 1Y (TTM)21.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.89%
Revenue 1Y (TTM)-89.67%
Revenue growth 3Y26.44%
Revenue growth 5Y68.05%
Sales Q2Q%625.83%
3.2 Future
The Earnings Per Share is expected to grow by 7.57% on average over the next years.
Based on estimates for the next years, FATE will show a small growth in Revenue. The Revenue will grow by 6.82% on average per year.
EPS Next Y-5.27%
EPS Next 2Y-2.24%
EPS Next 3Y3.55%
EPS Next 5Y7.57%
Revenue Next Year-82.21%
Revenue Next 2Y-76.05%
Revenue Next 3Y-60.3%
Revenue Next 5Y6.82%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FATE. In the last year negative earnings were reported.
Also next year FATE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.24%
EPS Next 3Y3.55%
5. Dividend
5.1 Amount
FATE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FATE THERAPEUTICS INC
NASDAQ:FATE (11/18/2024, 5:00:23 PM)
After market: 2.34 +0.07 (+3.08%)2.27
+0.25 (+12.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap258.51M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.23% | ||
| ROE | -44.26% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.18 | ||
| Quick Ratio | 9.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)21.2%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-5.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-89.67%
Revenue growth 3Y26.44%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y